You are on page 1of 2

9538 Federal Register / Vol. 72, No.

41 / Friday, March 2, 2007 / Notices

Reports Clearance Office on (410) 786– methodology to determine the timing 1995, as referenced in the Federal
1326. and amount of provider payments, but Acquisition Regulation 32.803(d) it is
Written comments and the methodology must reflect each hereby determined that the use of a no-
recommendations for the proposed provider’s share of total Medicare setoff provision is appropriate to
information collections must be mailed payments during a specified period of facilitate the private financing of a
or faxed within 30 days of this notice time. Grant funds may not be steam production facility at NCI-
directly to the OMB desk officer: OMB distributed to hospitals and SNFs that Frederick.
Human Resources and Housing Branch, are not in operation. States’ payment
Attention: Carolyn Lovett, New methodologies should specify the Findings
Executive Office Building, Room 10235, relevant time periods and any other 1. Despite an essentially static space
Washington, DC 20503, Fax Number: factors that will be considered in inventory, the cost of steam under NCI-
(202) 395–6974. distributing available grant funds Frederick’s interagency agreement with
Dated: February 22, 2007. according to the principles specified the Fort Detrick U.S. Army Garrison has
Michelle Shortt,
above, and are subject to approval by increased by 70% from 2003 to 2006. In
CMS. addition, despite numerous energy
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory Justification for Exception to saving projects accomplished over the
Affairs. Competition past 9 years, quantities of steam billed
[FR Doc. E7–3654 Filed 3–1–07; 8:45 am] by the Army to the NCI have remained
The Secretary has invoked his 20%–30% above amounts estimated/
BILLING CODE 4120–01–P authority to restore health care in measured through engineering methods.
impacted communities affected by 2. In response to the escalation in
Hurricane Katrina by offering this steam related energy costs/quantities, a
DEPARTMENT OF HEALTH AND unique funding opportunity which will
HUMAN SERVICES thorough review of steam production
enable States to make payments to assist alternatives was conducted. Based on
Centers for Medicare & Medicaid hospitals and SNFs that are paid under this analysis it was concluded that
a Medicare PPS, with the financial significant energy and cost savings
Services
pressures that may result from changing could be achieved through the
Notice of Single-Source Grant Award wage rates in those impacted construction of a new steam production
to Louisiana, Alabama, and Mississippi communities. For the reasons cited
facility and the subsequent severing of
for a Project Entitled, ‘‘Deficit above, the Secretary has directed the
ties to the existing Fort Detrick boiler
Reduction Act Hurricane Katrina Centers for Medicare & Medicaid
plant.
Healthcare Related Provider Services to offer a single-source award
3. On behalf of Potomac Edison
Stabilization’’ to the States of Louisiana, Alabama and
Company, APS Constellation, L.L.C. has
Mississippi.
AGENCY: Centers for Medicare & proposed a privately financed Energy
FOR FURTHER INFORMATION CONTACT:
Medicaid Services (CMS), HHS. Savings Performance Contract (ESPC) to
Wendy J. Taparanskas, PhD., Health construct the new steam facility.
ACTION: New Grant Awards. Insurance Specialist, Office of the Securing the private financing for this
Center Director, Centers for Medicaid project is dependent upon incorporation
Funding Amount: $160,000,000. and State Operations, Centers for
Period of Performance: February 12, of a no-setoff provision in the contract.
Medicare & Medicaid Services, Mail 4. Inclusion of the no-setoff provision
2007–September 30, 2009. Stop S2–26–12, 7500 Security
SUMMARY: The Secretary has authorized will enable the Contractor to secure
Boulevard, Baltimore, MD 21244, (410) financing with an interest rate that is
a total of $160 million in grant funds 786–5245.
available to all three States. Based on lower than the interest rate that would
Authority: Section 6201(a)(4) of the Deficit be obtained in the absence of the no-
each eligible IPPS hospital’s and SNF’s
Reduction Act of 2005 (DRA) . setoff provision. The Government will
share of total Medicare inpatient
(Catalog of Federal Domestic Assistance benefit directly from a lower interest
payments in the FEMA designated Program No. 93.779)
counties in calendar year 2005 (the rate in the form of lower interest
latest and most complete year of Dated: February 13, 2007. payments over the 20-year term of the
Medicare billing data available to us), Leslie V. Norwalk, repayment.
this funding is being allocated for each Acting Administrator, Centers for Medicare 5. Incorporating a no-setoff provision
State in the following proportions: 45 & Medicaid Services. will not increase the risk of the
percent to Louisiana ($71,633,492), 38 [FR Doc. E7–3655 Filed 3–1–07; 8:45 am] Government since the Basic Ordering
percent to Mississippi ($60,556,425) and BILLING CODE 4120–01–P Agreement requires that the Contractor
17 percent to Alabama ($27,810,083). guarantee that the energy and energy-
This grant program is to fund State related cost savings exceed the
payments to general, acute care DEPARTMENT OF HEALTH AND payments to the Contractor during the
hospitals, and skilled nursing facilities HUMAN SERVICES performance period following
in impacted communities that may face construction of the project. In the event
financial pressures because of changing National Institutes of Health that the savings fall below the level
wage rates that are not yet reflected in guaranteed by the Contractor, the
Notice of Determination and Findings;
Medicare PPS payment methodologies. Contractor will be responsible for
Authority To Incorporate a No-Setoff
The grant funds must be used by the crediting the difference to the
Commitment
States to make payments to all Medicare Government.
pwalker on PROD1PC71 with NOTICES

participating general hospitals, acute Upon the basis of the following 6. In accordance with the guidance set
care hospitals, and SNFs that are findings pursuant to authority of Title forth in FAR 32.803(d), a review of the
currently paid under a Medicare PPS in 31 U.S.C. Section 3727 and in proposed contractor’s financial status
the impacted communities. States have accordance with the Presidential revealed no significant indebtedness to
some flexibility in determining the delegation of authority dated October 3, the United States.

VerDate Aug<31>2005 18:44 Mar 01, 2007 Jkt 211001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\02MRN1.SGM 02MRN1
Federal Register / Vol. 72, No. 41 / Friday, March 2, 2007 / Notices 9539

Determination podocyte cell line with tightly drugs are stimulants or antidepressants.
Based on the foregoing, I hereby controlled conditional gene expression. However, currently there is no way to
determine that it is the Government’s The cell line has been conditionally tell in advance which medication will
best interests to approve the use of immortalized through the introduction be most helpful for a particular
Alternate 1 to the Clause at FAR 52.232– of the H-2Kb-tsA58 transgene, which is individual.
23 which authorizes incorporation of a a temperature-sensitive mutant of the The inventors have identified
no-setoff provision. SV40T antigen. Inducible gene haplotypes of latrophilin 3 (LPHN3) that
expression is tightly controlled through increase susceptibility for development
Dated: February 22, 2007.
two introduced transgenes, podocin- of ADHD. LPHN3 is a G-protein coupled
Daniel J. Frasier, rtTA and CMV-tTS, that produce a ‘‘Tet- receptor that is specifically expressed in
Head of the Contracting Activity, Director, on’’ system wherein gene expression is the brain’s mesolimbic system, which is
OAMP, OA, OM, National Institutes of Health. induced by tetracycline or doxycycline. associated with ADHD. The invention
[FR Doc. 07–960 Filed 3–1–07; 8:45 am] The combination of the two transgenes describes methods of identifying LPHN3
BILLING CODE 4140–01–M for Tet-on gene expression has resulted haplotypes in an individual for
in much tighter regulation and lower determining susceptibility for
background expression compared to development of ADHD. Identification of
DEPARTMENT OF HEALTH AND cells carrying the podocin-rtTA LPHN3 haplotypes in an ADHD-affected
HUMAN SERVICES transgene alone. individual may also make possible
National Institutes of Health Applications: Model system for study individualized drug treatment plans.
of glomerular disorders; Model system Applications: Identify individuals
Government-Owned Inventions; for podocyte cell biology. with enhanced susceptibility for ADHD;
Availability for Licensing Market: Glomerular disorders are a Use LPHN3 haplotype information to
major cause of chronic kidney disease. design individualized treatments.
AGENCY: National Institutes of Health, Approximately 20 to 35 percent of Inventors: Maximillian Muenke
Public Health Service, HHS. patients requiring renal replacement (NHGRI), Mauricio Arcos-Burgos
ACTION: Notice. therapy have a glomerular disorder. (NHGRI), and F. Xavier Castellanos
Inventors: Jeffrey B. Kopp (NIDDK) et (NIMH).
SUMMARY: The inventions listed below al.
are owned by an agency of the U.S. Patent Status: U.S. Provisional
Relevant Publication: T Shigehara, C
Government and are available for Application No. 60/850,972 filed 11 Oct
Zaragoza, C Kitiyakara, H Takahashi, H
licensing in the U.S. in accordance with 2006 (HHS Reference No. E–312–2006/
Lu, M Moeller, LB Holzman, and JB
35 U.S.C. 207 to achieve expeditious 0-US–01).
Kopp. Inducible podocyte-specific gene
commercialization of results of Licensing Status: Available for
expression in transgenic mice. J Am Soc
federally-funded research and exclusive or nonexclusive licensing.
Nephrol. 2003 Aug;14(8):1998–2003.
development. Foreign patent Patent Status: HHS Reference No. E– Licensing Contact: Tara Kirby, PhD.;
applications are filed on selected 049–2007/0—Research Tool. 301/435–4426; tarak@mail.nih.gov.
inventions to extend market coverage Licensing Status: This technology is A Fertility Test To Detect Ovarian
for companies and may also be available available as a research tool under a Autoimmune Disease Using Human
for licensing. Biological Materials License. Recombinant MATER Protein
ADDRESSES: Licensing information and Licensing Contact: Tara L. Kirby,
copies of the U.S. patent applications PhD.; 301/435–4426; Description of Technology: The
listed below may be obtained by writing tarak@mail.nih.gov. inventors have identified MATER, a
to the indicated licensing contact at the Collaborative Research Opportunity: gene that plays an important role in
Office of Technology Transfer, National The NIDDK Kidney Disease Section is fertility, and have shown that antibodies
Institutes of Health, 6011 Executive seeking statements of capability or against MATER protein are detected at
Boulevard, Suite 325, Rockville, interest from parties interested in higher frequencies in women
Maryland 20852–3804; telephone: 301/ collaborative research to further experiencing infertility and irregular
496–7057; fax: 301/402–0220. A signed develop, evaluate, or commercialize a menstrual periods than in healthy
Confidential Disclosure Agreement will model system for the study of women. The discovery of MATER as an
be required to receive copies of the glomerular disorders. Please contact important factor in autoimmune-
patent applications. Jeffrey B. Kopp, MD, by phone (301/ mediated ovarian dysfunction will
594–3403), fax (301/402–0014) or e-mail facilitate diagnosis and treatment of
Model for Study of Glomerular (jbkopp@nih.gov) for more information. these disorders. In addition to its critical
Disorders: Conditionally-Immortalized role in ovarian autoimmunity, the
Mouse Podocyte Cell Line With Tet-on- Latrophilin 3, a Gene Involved in inventors have also discovered that the
Regulated Gene Expression Attention Deficit Hyperactivity MATER gene plays an essential role in
Description of Technology: Podocytes, Disorder embryonic development.
cells of the visceral epithelium in the Description of Technology: Attention The invention discloses the MATER
kidneys, are a key component of the Deficit Hyperactivity Disorder (ADHD) gene, MATER protein and MATER-
glomerular filtration barrier. As such, is the most common behavioral disorder specific antibodies. Also disclosed are
they play a vital role in glomerular in childhood, and is estimated to affect methods and kits for evaluating female
disorders, which are a major cause of three to five percent of people in the infertility through detection of an
chronic kidney disease. Examples of United States, both children and adults. abnormal autoimmune response, an
these disorders include focal segmental Treatment typically involves a abnormal MATER gene, or abnormal
pwalker on PROD1PC71 with NOTICES

glomerulosclerosis, membranous combination of behavior modification, MATER protein expression.


glomerulonephritis, minimal change educational interventions, and Applications: Diagnostic test for
disease, and diabetic nephropathy. medication. There are a variety of women suffering from infertility or
The inventors have developed a medications available for treatment of irregular menstrual periods; Tool for the
conditionally-immortalized mouse ADHD; the most frequently prescribed study of early embryonic development;

VerDate Aug<31>2005 18:44 Mar 01, 2007 Jkt 211001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\02MRN1.SGM 02MRN1